Type 1 - New Molecular Entity and Type 4 - New Combination
Type 2 - New Active Ingredient and Type 3 - New Dosage Form
Type 2 New Active Ingredient and Type 4 New Combination
Type 3 - New Dosage Form and Type 4 - New Combination
Type 5 - New Formulation or New Manufacturer
Type 6 - New Indication (no longer used)
Type 7 - Drug Already Marketed without Approved NDA
Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
Type 9 - New indication submitted as distinct BLA, consolidated